Chronic creatine kinase elevation not associated with HMG-CoA reductase inhibitor treatment

Annals of Pharmacotherapy

Volumn 33, Issue 2, 1999, Pages 163-166

  Lin, Jennifer C ^a,b   Ito, Matthew K ^b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Creatine kinase; Hydroxymethylglutaryl coenzyme A reductase inhibitors

Indexed keywords

COLESTYRAMINE; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG MONITORING; DRUG SAFETY; ENZYME ASSAY; HUMAN; HYPERLIPIDEMIA; KIDNEY FAILURE; MALE; MYOSITIS; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT PLANNING;

CREATINE KINASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KIDNEY FAILURE; MALE; MIDDLE AGED; PRAVASTATIN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033020181     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18120     Document Type: Article

References (25)

1. Bradford RH, Shear CL, Chremos AN, Dujovne C, Franklin FA, Hesney M, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia. Am J Cardiol 1990:66(suppl):44B-55B.
2. Ito MK, Shabetai R. Primary care pharmacotherapist in a VA based cardiac rehabilitation program. Int Pharm Abstracts 1992;27:P-475D.
3. Miles BJ. Screening for adenocarcinoma of the prostate. Henry Ford Hosp Med J 1989;37(1):5-7.
4. Tsung SH. Creatine kinase isoenzyme patterns in human tissue obtained at surgery. Clin Chem 1976;22:173-5.
5. Coolen RB, Pragay DA, Nosanchuk JS, Belding R. Elevation of brain-type creatine kinase in serum from patients with carcinoma. Cancer 1979;44:1414-8.
6. Carney DN, Zweig MH, Ihde DC, Cohen MH, Makuch RW, Gazdar AF. Elevated serum creatine kinase BB levels in patients with small cell lung cancer. Cancer Res 1984;44:5399-403.
7. Strom S, Bendz R. Creatine kinase and lactate dehydrogenase isoenzymes in stage D prostatic carcinoma. Clin Chim Acta 1986;159:219-28.
8. Hoag GN, Franks CR, Decoteau WE. Creatine kinase isoenzymes in serum of patients with cancer of various organs (letter). Clin Chem 1978; 24:1654.
9. Silverman LM, Dermer GB, Zweig MH, Van Steirteghem AC, Tokes ZA. Creatine kinase BB: a new tumor-associated marker. Clin Chem 1979;25:1432-5.
10. El-Shribiny A, Bharvaga A, Fitzpatrick J, Murphy GP. Creatine kinase isoenzyme (CK-BB) by RIA as a follow-up marker in stage D cancer of the prostate: comparison with PAP RIA. J Surg Oncol 1985;28:232-6.
11. Zarghami N, Yu H, Diamandis EP, Sutherland DJA. Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultra-sensitive time-resolved immunnfluorometric technique. Clin Biochem 1995;28:243-53.
12. Zweig MH, Ihde DC. Assessment of serum radioimmune and enzymatic prostatic acid phosphatase and radioimmune creatine kinase BB for monitoring response to therapy in metastatic prostatic carcinoma. Cancer Res 1985;45:3945-50.
13. Wong SS, Wu AHB, Fritsche HA. Reassessment of creatine kinase BB as a marker for cancer of the prostate, breast, and lung. Clin Chem 1987; 33:809-11.
14. Fair WR. Biochemical markers for prostatic carcinoma. Prog Clin Biol Res 1987;239:659-80.
15. Dickey W, Carson CA, Andrews WJ, Crowe PF. Apparent elevation of serum CK-MB not due to acute myocardial infarction. Br J Clin Pract 1992;46(2, summer):149-50.
16. Ito MK, Shabetai R. Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease. Am J Cardiol 1997;80:799-802.
17. The Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993;71:1408-14.
18. Jones P, Kafonek S, Laurora I, Hunninghake D, CURVES investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
19. Veerkamp JH, Smit JWA, Benders AAGM, Oosterhof A. Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells. Biochim Biophys Acta 1996;1315:217-22.
20. Piemo S, De Luca A, Tricarico D, Roselli A, Natuzzi F, Ferrannini E, et al. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Pharmacol Exp Ther 1995; 275:1490-6.
21. Singhal PC, Earth RH, Ginsberg NS, Lynn R. Determinants of serum creatine kinase activity in dialysis patients. Am J Nephrol 1988;8:220-4.
22. Ma KW, Brown DC, Steele BW. Serum creatine kinase MB isoenzyme activity in long-term hemodialysis patients. Arch Intern Med 1981;141: 164-6.
23. Jaffe AS, Ritter C, Meltzer V, Harter H, Roberts R. Unmasking artifactual increases in creatine kinase isoenzymes in patients with renal failure. J Lab Clin Med 1984;104:193-202.
24. Weseley SA, Byrnes A, Alter S, Solangi KB, Goodman AI. Presence of creatine phosphokinase brain band in the serum of chronic renal disease patients. Clin Nephrol 1977;8:345-8.
25. Bogden PE, Koontz LM, Williamson P, Abbott RD. The physician and pharmacist team. An effective approach to cholesterol reduction. J Gen Intern Med 1997;12:158-64.